Profiel
Dr. C.
R.
Cory is Global Head-Business Development at biOasis Technologies, Inc.
Dr. Cory was previously employed as Vice President-Business Development by MIGENIX, Inc.
He received his MBA from Wilfrid Laurier University and a doctorate degree from The University of Waterloo.
Eerdere bekende functies van C. Robert Cory
| Bedrijven | Functie | Einde |
|---|---|---|
MIGENIX, Inc.
 MIGENIX, Inc. Pharmaceuticals: MajorHealth Technology MIGENIX, Inc. develops pharmaceutical drugs. It focuses on advancing therapy, improving health, and enriching life by developing and commercializing drugs in the areas of infectious and degenerative diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C (Phase II), the prevention of catheter-related infections (Phase III), the treatment of neurodegenerative diseases (Phase I/II) and the treatment of acne (Phase II). MIGENIX was founded in 1993 and is headquartered in Vancouver, Canada. | Corporate Officer/Principal | 24-03-2010 |
| BIOASIS TECHNOLOGIES INC. | Corporate Officer/Principal | - |
Opleiding van C. Robert Cory
| The University of Waterloo | Doctorate Degree |
| Wilfrid Laurier University | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| BIOASIS TECHNOLOGIES INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
MIGENIX, Inc.
MIGENIX, Inc. Pharmaceuticals: MajorHealth Technology MIGENIX, Inc. develops pharmaceutical drugs. It focuses on advancing therapy, improving health, and enriching life by developing and commercializing drugs in the areas of infectious and degenerative diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C (Phase II), the prevention of catheter-related infections (Phase III), the treatment of neurodegenerative diseases (Phase I/II) and the treatment of acne (Phase II). MIGENIX was founded in 1993 and is headquartered in Vancouver, Canada. | Health Technology |
